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Summary. The epidemiology oftwo cases of 
pseudallescheriasis in organ transplant pa-
tients are described and the disease in that 
population is reviewed. Disseminated hospi-
tal-acquired infection occurred in a liver 
transplant recipient and was fatal despite 
therapy with miconazole. A heart transplant 
recipient developed localized disease follow-
ing soil contamination of soft tissue trauma 
which was cured with surgical resection and 
miconazole therapy. ltraconazole showed in 
vitro activity against Pseudallescheria boy-
dii and should be evaluated in pseudallesche-
riasis. P. boydii infections are important 
complications of transplantation and 
should be considered in the differential 
diagnosis of community-acquired as well as 
nosocomial fungal infections in this popula-
tion. 
Zusammenfassung. Es werden zwei Fiille 
von Pseudallescheriasis bei Transplanta-
tionspatienten beschrieben, und die Litera-
tur hierUber wird zusammenfassend gewich-
tet. Eine disseminierte Hospitalinfektion 
wurde an einem Lebertransplantationspa-
tienten beobachtet, die trotz Miconazoi-
Therapie tOdlich ausging. Ein Herztrans-
plantationspatient entwickelte cine Lokalin-
fektion nach einer Erdbodenkontamination 
bei einem Weichteiltrauma, die durch 
Resektion und Miconazolgaben geheilt 
werden konnte. Itraconazol erwies sich in 
vitro als aktiv gegen P. boydii und sollte bei 
Pseudallescheriasis geprUft werden. P. boy-
dii-Infektionen stellen wichtige Komplika-
tionen bei Organtransplantationen dar und 
sollten differentialdiagnostisch bei Umge-
bungsinfekten wie bei nosokomialen Infek-
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tionen dieser Patientengruppe in Erwagung 
gezogen werden. 
Introduction 
Pseudallescheria boydii is an ubiquitous soil 
fungus that most commonly causes myceto-
mas [I]. The most common non-mycetoma 
site of isolation is the lung [2]. Disseminated 
disease is rare but occurs in immunocom-
promised hosts [3, 4]. The resistance of this 
organism to many antifungal agents includ-
ing amphotericin B complicates therapy [5, 
6]. In vitro sensitivity to miconazole and 
ketoconazole has been demonstrated but 
susceptibility data to those agents [3, 7] and 
newer azote compounds is limited. The most 
common route of soft tissue infection is 
through skin inoculation [8]; pulmonary 
infection occurs through inhalation of 
spores and occurs primarily in immunocom-
promised hosts [4, 9]. However, pseudalle-
scheriasis is not usually considered as a 
potential etiology of hospital-acquired fun-
gal infections [9]. In this report we describe 
two organ transplant patients with pseudal-
lescheriasis, including one infection which 
was nosocomial in origin. In addition, we 
review the epidemiology of pseudallescheri-
asis in transplantation and evaluate the in 
vitro susceptibilities of the isolates. 
Patients 
In vitro susceptibility methods. All speci-
mens were inoculated onto Sabouraud's 2% 
dextrose agar and the isolates identified on 
the basis of morphological features [I 0]. In 
vitro susceptibilities were performed by agar 
dilution replicate plate assay as previously 
described [II, 12]. Briefly, ketoconazole and 
miconazole (Janssen Pharmaceutica, Inc., 
Piscataway, NJ, USA) were dissolved in 
100 %dimethyl sulfoxide (D M SO), itracon-
azole (Janssen Pharmaceutica) was dis-
solved in 85% ethyl alcohol in IN HCl, 
fluconazole (Pfizer Central Research, 
Groton CT) was dissolved in sterile water, 
amphotericin B (E. J. Squibb & Sons, Inc., 
Princeton, NJ, USA) was dissolved in 100% 
DMSO, and flucytosine (Hoffmann-La-
Roche, Inc. Nutley, NJ, USA) was dissolved 
in distilled water to achieve a stock solution 
of 1,000 pgfml for each drug. Further 
dilutions were made in distilled water to give 
final concentrations from 0.006 to 50 pgf ml 
in the agar plates. The agar used for 
ketoconazole, miconazole, itraconazole, 
and fluconazole was Kimmig agar (E. 
Merck, Darmstadt, FRG), for amphotericin 
B antibiotic medium #3 in purified agar 
(Difco, Inc. Detroit, MI, USA) was used, 
and for flucytosine, yeast nitrogen base agar 
(Difco, Inc.) was used. The inoculum used 
was 5 x I 04 organisms I ml inoculated with a 
Steers replicator, which delivered 0.003 ml of 
each organism giving a final inoculum of 1.5 
x 102 organisms. After 48 h at 25 ·c, the 
plates were read for growth with the minimal 
inhibitory concentration (MIC) defined as 
the lowest concentration of drug with no 
visible fungal growth. 
Case I. A 22-year-old man had been well 
until 7 weeks prior to admission when a 
depressed skull fracture from a motor 
vehicle accident required phenytoin prophy-
laxis. He developed hepatic failure secon-
dary to phenytoin hepatitis and in August, 
1985 he was admitted to the University of 
Michigan Medical Center for liver trans-
plantation. After liver transplantation, he 
was immunosuppressed with methylpred-
nisolone and cyclosporine. Seven days post-
operatively he developed abdominal fascia 
infection and peritonitis and was treated 
with multiple antibiotics including tobra-
mycin, vancomycin, clindamycin, and cefo-
taxime. One week post-transplantation, a 
liver biopsy showed acute rejection and he 
was given additional steroids and anti-
thymocyte globulin. 
On day 25 post-transplant, 37 days after 
admission, a chest radiograph revealed a 
new left upper lobe pulmonary nodule and a 
transthoracic needle biopsy was done. 
Periodic acid Schiff (PAS) stain of the 
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specimen revealed hyphal elements on 
microscopic examination. Amphotericin B 
was begun for presumed Aspergillus infec-
tion and other antibiotics were discontinu-
ed. The biopsy specimen and sputum were 
inoculated onto Sabouraud's 2% dextrose 
agar. Two days later both cultures grew P. 
boydii as identified on the basis of morpho-
logical features [10]. In vitro susceptibilities 
performed by agar dilution replicate plate 
assay are shown in Table 1. Oral ketoconazo-
le 400 mg/ day was added to the amphoteri-
cin B. A serum ketoconazole level was 
measured at 4 pgj ml. Because of progressive 
pulmonary lesions, ketoconazole and am-
photericin B were discontinued after 12 days 
of therapy and intravenous miconazole was 
begun at a dose of 600 mg every 8 h. The 
nodular pulmonary densities stabilized but a 
lower lobe infiltrate developed on chest 
radiograph. Sputum cultures grew Enterob-
acter aerogenes and piperacillin and tobra-
mycin were begun. He developed progressi-
ve renal insufficiency, respiratory failure, 
and disseminated intravascular coagula-
tion. He died 43 days post-transplant. 
Autopsy revealed cavitary lesions in both 
lungs and a 3 x 3 em cavitary brain lesion in 
the right parietal area. All lesions had fungal 
hyphae seen on microscopic examination. 
Case 2. A 58-year-old man, admitted to Yale 
New Haven Hospital, underwent cardiac 
transplantation for idiopathic cardiomyo-
pathy in March, 1986, and was immunosup-
pressed with prednisone, azathioprine, and 
cyclosporine. He did well until June, 1986, 
when his right knee became swollen after a 
bicycle fall, but there was no break in skin 
integrity. The knee swelling resolved, but 
two weeks following the injury, he sustained 
superficial breaks in the skin while working 
under a house. In August, 1986, he presented 
with knee pain and swelling. Examination 
revealed a warm, tender, fluctuant prepatel-
lar region with no adenopathy or sinus tracts 
detected. The prepatellar bursa was aspira-
ted and contained thick purulent material 
that later grew P. boydii on culture. The 
following day a second bursa aspiration 
Table 1. Susceptibilities of clinical P. boydiiisolates 
Minimallnhbitory Con-
centration (l.tg I ml) 
Drug Strain 1 Strain 2 
Amphotericin 8 >50 50.0 
Flucytosine >50 >50 
Ketoconazole 1.56 3.12 
Miconazole 0.20 0.20 
Fluconazole 50.0 50.0 
ltraconazole 6.25 6.25 
revealed similar findings and the cultures 
were again positive for P. boydii. The patient 
was not treated. He returned to his previous 
active status and his immunosuppression 
was continued unchanged. Over a course of 
4 months, cystic lesions developed over the 
medial aspect of his right knee and he was 
admitted to Yale New Haven Hospital in 
December, 1986. Examination was normal 
except for multiple cystic lesions on the 
medial aspect of the right knee. The largest 
cyst was 2 em x 3 em in size. No joint fluid was 
apparent. The peripheral white blood cell 
count was 6,300jmm3 with 83% polymor-
phonuclear neutrophils. The cystic lesion 
was aspirated and the fluid contained 
290,000 white blood cells/mm3, 95% were 
polymorphonuclear neutrophils. The cystic 
fluid glucose was 22 mg/ dl, with a serum 
glucose of I 09 mgj dl. PAS stain of the fluid 
showed multiple branching septate hyphae 
and the culture grew P. boydii. In vitro 
susceptibilities are shown in Table 1. 
Radiographs showed no bone involvement 
and a magnetic resonance study confirmed 
the lesions to be in the prepatellar bursa and 
superficial to the joint space (Fig. 1). 
He was treated with miconazole using a 
dose of 600 mg every 8 h. Three days after 
antifungal therapy was begun he underwent 
surgical debridement of all the cystic lesions. 
Surgical findings confirmed the lesions to be 
superficial to the joint space and resection of 
the entire cystic structures was performed. 
No granules were detected at the time of 
resection. Antifungal therapy was continued 
for 2 weeks post-operatively for a total 
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Figure I. Pscudallcschcriasis. Magnetic resonance scan of 
right knee from patient 2. Arrows demonstrate the cystic 
lesions in the pre-patellar bursa. 
miconazole dose of 30 g. He tolerated 
therapy well. His cyclosporine levels did not 
rise. After 2 years of follow-up, he had no 
recurrence. 
Discussion 
These cases illustrate important epidemiolo-
gic and diagnostic aspects of Pseudallesclze-
ria hoydii infections in organ transplanta-
tion which are particularly critical in the 
successful diagnosis and treatment of infec-
tion in these hosts. Patient I demonstrates 
the difficulty in diagnosing Pseudallescheria 
infection by histopathology alone. Both 
A.lfJergillus spp. and P hoydii can appear in 
tissue sections as branched septate hyphae. 
The diagnosis can be particularly difficult 
since both organisms can present as cavitary 
or nodular pulmonary disease in immuno-
compromised patients. Because aspergillo-
sis is more common, that disease is often 
diagnosed empirically and therapy begun 
with amphotericin B, as was done in patient 
I. Most isolates of P boydii show in vitro 
resistance to amphotericin B [6], as was the 
case in both of these patients. Thus, while 
tissue biopsy is needed to prove invasive 
disease, isolation in culture of the organism 
from tissue specimens is needed to confirm 
Pseudallescheria infection [ 14]. 
In addition, patient I emphasizes the 
importance of considering the diagnosis of 
pseudalleschiasis in immunocompromised 
patients even when they have been hospitali-
zed for an extended period of time. Previous 
cases of pscudallescheriasis have been 
diagnosed several weeks after admission to 
the hospital [14, 15]. However, the nosoco-
mial occurrence of infection in those 
previous transplant patients was not discus-
sed. Previously reported patients were 
immunocompromised prior to admission to 
the hospital. In those cases P boydii 
infection could represent either infection 
from the patient's endogenous flora and be 
considered hospital-associated or it could 
have been a true hospital-acquired infection 
[ 16]. Patient I was not likely to be colonized 
or infected on admission as he was 
immunocompetent until admission to the 
hospital and received a liver transplant. 
Thus, his nosocomial infection likely repres-
ented true hospital-acquired disease. 
In contrast, the soft tissue infection in 
patient 2 most likely resulted from inocula-
tion of the fungus from soil into the 
previously traumatized knee. Most often 
inoculation in that fashion results in the 
mycetoma form of the disease with sinus 
tract and granule formation. While his 
indolent course is compatible with a 
mycetoma-like disease, sinus tract forma-
tion was not present and no granules were 
noted. Bone and soft tissue infections have 
been not successfully treated with a combi-
ned medical and surgical approach. Our 
patient was successfully treated with com-
plete surgical removal of the lesion combi-
ned with a two week course of miconazole, 
but optimal duration of therapy is not 
known. In a similar cystic Pseuda!lescheria 
infection in a non-compromised patient, 
complete surgical removal combined with 4 
months of ketoconazole was effective [g]. In 
cases where surgical removal of the lesions is 
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not possible or is incomplete, prolonged 
antifungal therapy may be necessary [5, 17]. 
Pseudallescheria boydii infections have 
been previously reported in at least four 
transplant recipients [7, 13-15]. Fatal disse-
minated disease that included central ner-
vous system involvement has been reported 
from three transplant patients. One heart 
transplant patient developed pseudallesche-
riasis after a prolonged course of amphoteri-
cin B for pulmonary aspergillosis which may 
have predisposed her to resistant Pseudal/e-
scheria infection; she was unsuccessfully 
treated with miconazole [ 13]. A kidney 
transplant patient was unsuccessfully trea-
ted with amphotericin B and flucytosine 
[15]. A bone marrow recipient developed 
disseminated disease while on ketoconazole 
for fungal prophylaxis and was treated 
unsuccessfully with empiric amphotericin B, 
with disseminated P. boydii detected on 
autopsy [14]. Another heart transplant 
recipient had nodular pulmonary disease 
that was treated with an extended course of 
ketoconazole and responded without surgi-
cal intervention [7]. 
In vitro susceptibilities have shown 
resistance of P. boydiito amphotericin Band 
to flucytosine, as noted in both our patients 
[3]. In vivo response to those agents is poor, 
as was seen in our patient I. Reported M I Cs 
ofmiconazoleto P. boydiiarecloseto0.2pg/ 
ml, as noted with both of our isolates [3, 7]. 
Achievable peak serum levels of miconazole 
exceed I pg/ ml with intravenous doses of> 
9 mg/ kg [3]. Miconazole has been success-
fully used in pseudallescheriasis [5], inclu-
ding our patient 2 [5]. Ketoconazole offers 
the advantage of prolonged oral therapy but 
M I Cs ofketoconazole to P. boydii are higher 
than those of miconazole and often exceed 
achievable serum concentrations. In our 
isolates the MICs were close to the levels 
achieved with administration of 400 mg of 
ketoconazole. However, in vitro susceptibi-
lities to ketoconazole do not always correla-
te with clinical response as successful 
therapy has been reported in patients with 
strains showing in vitro resistance [7]. Use 
of miconazole and ketoconazole in trans-
plant recipients is further complicated 
because these agents can increase serum 
cyclosporine levels and in liver transplant 
recipients may not be properly metabolized 
[18]. Itraconazole showed in vitro activity 
against both isolates although the MIC was 
slightly higher than that of ketoconazole. 
Since itraconazole may interfere less with 
cyclosporine metabolism, it could be an 
alternative drug to use in transplant patients 
with Pseudal/escheria infection. Significant-
ly less in vitro activity of fluconazole against 
P. boydii was noted, but the correlation 
between susceptibility results and in vivo 
response for fluconazole is particularly poor 
[19]. 
These two cases show that Pseudal-
lescheria infections can occur as dis-
seminated or localized disease in trans-
plant recipients. In addition, these cases 
emphasize that while soil inoculation is the 
usual route of soft tissue infection, nosoco-
mial infection with P. boydii can occur and 
should be considered in the differential 
diagnosis of hospital acquired fungal infec-
tions in the transplant population. Dissemi-
nated disease is often fatal despite maximal 
therapy but localized disease may be cured 
with combined medical and surgical therapy 
even with necessary continuation of severe 
immunosuppression in these patients. ltru-
conazole wus found to have in vitro activity 
against P. boydii and may afford another 
option for prolonged therapy of pseudalle-
scheriasis. 
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